Revenue: As of FY2025 Q3, the actual value is USD 354.26 M, beating the estimate of USD 339.1 M.EPS: As of FY2025 Q3, the actual value is USD 1.43, beating the estimate of USD 1.3875.EBIT: As of FY2025 Q3, the actual value is USD 217.92 M.<h3>Segment Revenue</h3><ul><li>Royalties: $236,038,000 for the three months ended September 30, 2025, compared to $155,061,000 for the same period in 2024, representing a 52% increase. For the nine months ended September 30, 2025, royalties were $609,869,000, compared to $400,572,000 in 2024, a 52% increase.</li><li>Product Sales, Net: $94,228,000 for the three months ended September 30, 2025, compared to $86,659,000 for the same period in 2024, a 9% increase. For the nine months ended September 30, 2025, product sales were $253,779,000, compared to $224,128,000 in 2024, a 13% increase.</li><li>Revenues Under Collaborative Agreements: $23,998,000 for the three months ended September 30, 2025, compared to $48,364,000 for the same period in 2024, a 50% decrease. For the nine months ended September 30, 2025, revenues were $81,196,000, compared to $92,616,000 in 2024, a 12% decrease.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income: $175,225,000 for the three months ended September 30, 2025, compared to $137,011,000 for the same period in 2024. For the nine months ended September 30, 2025, net income was $458,480,000, compared to $307,079,000 in 2024.</li><li>Operating Income: $217,921,000 for the three months ended September 30, 2025, compared to $163,197,000 for the same period in 2024. For the nine months ended September 30, 2025, operating income was $561,897,000, compared to $375,974,000 in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Provided by Operating Activities: $432,529,000 for the nine months ended September 30, 2025, compared to $300,597,000 in 2024.</li><li>Net Cash Provided by (Used in) Investing Activities: $195,975,000 for the nine months ended September 30, 2025, compared to -$292,203,000 in 2024.</li><li>Net Cash (Used in) Provided by Financing Activities: -$324,689,000 for the nine months ended September 30, 2025, compared to $27,554,000 in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Halozyme Therapeutics, Inc. expects royalty revenue to grow further due to anticipated increasing partner product sales of DARZALEX SC, Phesgo, and VYVGART Hytrulo, and sales of recently launched ENHANZE partner products, TECENTRIQ SC and OCREVUS SC by Roche, RYBREVANT SC by Janssen, and Opdivo Qvantig by BMS.</li><li>Non-Core Business: The company has agreed to acquire Elektrofi, Inc., a biopharmaceutical company, for $750 million in upfront consideration and up to three $50 million milestone payments contingent upon three separate product regulatory approvals. The transaction is expected to close in the fourth quarter of 2025.</li></ul>

Halozyme Therap | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 354.26 M